Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report.
about
The Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ TransplantationSurveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR.A Systematic Review and Meta-analysis of Prophylactic versus Pre-emptive Strategies for Preventing Cytomegalovirus Infection in Renal Transplant Recipients.Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy.IL-23 plasma level is strongly associated with CMV status and reactivation of CMV in renal transplant recipients.Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patientsCytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients.Cytomegalovirus in transplantation - challenging the status quo.A case report of CMV lymphadenitis in an adult kidney transplant recipientImproving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation.Cytomegalovirus immunoglobulin decreases the risk of cytomegalovirus infection but not disease after pediatric lung transplantation.Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.Does the immune system naturally protect against cancer?The Cell Biology of Cytomegalovirus: Implications for Transplantation.Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience.Simultaneous pancreas/kidney transplant recipients are predisposed to tissue-invasive cytomegalovirus disease and concomitant infectious complications.The effect of different immunoprophylaxis regimens on post-transplant cytomegalovirus (CMV) infection in CMV-seropositive liver transplant recipients.Correlation between CMV Infection and Post-transplantation New-onset Diabetes Mellitus.Early cytomegalovirus-specific T-cell response and estimated glomerular filtration rate identify patients at high risk of infection after renal transplantation.Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy.Primary Cytomegalovirus Infection Significantly Impacts Circulating T Cells in Kidney Transplant Recipients.Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.The impact of early cytomegalovirus infection after kidney transplantation on long-term graft and patient survival.Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients.Cytomegalovirus & Epstein Barr Virus serostatus as a predictor of the long-term outcome of kidney transplantation.Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation.Prophylaxis versus preemptive protocols for CMV: do they impact graft survival?Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial.Effect of cytomegalovirus prophylaxis with acyclovir on renal transplant survival.Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.Simultaneous Monitoring of Cytomegalovirus-Specific Antibody and T-cell levels in Seropositive Heart Transplant RecipientsQuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity
P2860
Q28085440-C2CEA5C0-CAAA-4005-8C99-49133A9158DBQ33591729-26322ECB-F68A-4F78-A915-A501B1E6DB0CQ33871850-B092D646-FBB1-45DA-9876-5D7CFAA3DBEDQ33912913-CDCB89F0-6DE7-49BC-B159-C3782A0A2394Q34592551-A630DC60-BBB2-4FBE-BA50-5E0BC8A1D20DQ36156499-029054ED-A742-4B83-9731-CFC0AD33D81EQ36321541-BA4ECD24-407F-465C-95BA-65DECFCC06DBQ36728782-4E87512F-8271-418F-A64C-7AFBA93F844FQ36787493-963908D6-2007-4AAB-9BF6-964388B749ECQ36994746-3A7F9E4D-515D-4E22-B6FC-C0886DABE7CDQ37065216-A94F1737-E5F3-462E-BD1E-123F395AE69DQ37304893-98A6F94C-7398-4C88-BBB7-B0F008169576Q37407845-DD115768-9B5C-4BC0-8BC1-7108A24FC18FQ37409489-39F2E8C7-2F02-40CF-9FFB-49B0D4D970D8Q37949634-D39561C5-F135-44E0-8294-B4A812F5C738Q37965695-3FB33AD7-85BF-415F-9BBC-5000C0040F3CQ38214640-67F3EAB3-22E1-4CC3-8C91-AB289F550F45Q38779938-58016D7B-229A-4EEC-B822-99294B23917CQ39502888-EF40E053-888C-4B69-807F-040E44433DF3Q40139857-ED90BA76-2C05-4D25-BE4A-B596B071D20CQ40173113-F43BB9F3-028A-4C10-B6C3-A9006236E800Q40512277-39B5AE31-06E7-4ED1-A07F-EB84FC522FFDQ40791125-889CC806-F2AE-4A14-AF67-93EEB911F345Q40956620-49506715-A1F6-4451-9659-D59CC5899E0DQ41089597-6EAD5BF5-4551-4BB9-A8D9-F2DE369C5E64Q41342348-A63A1445-1560-431A-833A-A47C7CC12054Q41500588-6B89E837-F83D-495D-AF32-8D2F70E604ADQ42248317-FDFA184A-7014-436D-94AD-11140E72557CQ42252471-5A30CCE1-36BB-4F28-BF76-21860CBBE0F4Q42278126-33095014-AEF7-44A4-91E7-FE591C2DB982Q42281180-EB60E8CB-1C49-4BA7-95B5-4FFC6C863A64Q43653857-D7AFB618-F3D6-42FE-8108-70D61604C8C7Q44003429-2CE0AF83-533F-43CE-A9B2-A453F86429C9Q44407642-CC903ADB-DE67-44DF-B7FE-B19E6D454B00Q46733515-F58F1601-5586-4E91-A6CA-E75F50236F40Q47605886-3DEB0D33-C5C7-46A7-8500-23C6D9C0937AQ57568998-5B7BB2FC-EFD3-44B8-8EB8-489D5D5C2340Q58074723-2D8532C4-5C97-41EA-8966-0C237067648D
P2860
Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Cytomegalovirus prophylaxis an ...... ative transplant study report.
@en
Cytomegalovirus prophylaxis an ...... ative transplant study report.
@nl
type
label
Cytomegalovirus prophylaxis an ...... ative transplant study report.
@en
Cytomegalovirus prophylaxis an ...... ative transplant study report.
@nl
prefLabel
Cytomegalovirus prophylaxis an ...... ative transplant study report.
@en
Cytomegalovirus prophylaxis an ...... ative transplant study report.
@nl
P2860
P921
P1476
Cytomegalovirus prophylaxis an ...... ative transplant study report.
@en
P2093
Andrea Ruhenstroth
Bernd Döhler
P2860
P304
P356
10.1111/J.1600-6143.2004.00451.X
P407
P577
2004-06-01T00:00:00Z